FEMSTAT 3
Clinical safety rating: caution
Comprehensive clinical and safety monograph for FEMSTAT 3 (FEMSTAT 3).
Butoconazole nitrate, an imidazole antifungal, inhibits fungal cytochrome P450 14α-demethylase, preventing ergosterol synthesis and disrupting fungal cell membrane integrity.
| Metabolism | Minimal systemic absorption; primarily metabolized in the liver via oxidation and conjugation. |
| Excretion | Following topical vaginal administration of butoconazole nitrate, approximately 5% of the dose is absorbed systemically. The absorbed fraction is primarily metabolized in the liver and excreted via the biliary/fecal route. Renal excretion accounts for less than 3% of the administered dose. |
| Half-life | The terminal elimination half-life of butoconazole following topical vaginal administration is approximately 21-24 hours. This prolonged half-life supports once-daily dosing for 3 days in the treatment of vulvovaginal candidiasis. |
| Protein binding | Butoconazole is extensively bound to plasma proteins, primarily albumin, with a binding of approximately 98-99%. |
| Volume of Distribution | Due to low systemic absorption after topical vaginal administration, the volume of distribution (Vd) for the absorbed fraction is not well characterized. However, based on systemic studies of similar azole antifungals, the apparent Vd is estimated to be large (> 200 L), indicating extensive tissue distribution. For topical vaginal use, the local Vd is not clinically relevant. |
| Bioavailability | The systemic bioavailability of butoconazole after topical vaginal administration is approximately 5% (range 1-10%). This low systemic absorption minimizes systemic side effects while maintaining high local concentrations for antifungal efficacy. |
| Onset of Action | Clinical improvement (reduction in symptoms such as itching, burning, and discharge) is typically observed within 24-72 hours after initiating therapy. However, symptomatic relief may begin as early as 12-24 hours after the first dose. |
| Duration of Action | The therapeutic effect, as measured by mycological cure, persists for the 3-day treatment course and beyond. With once-daily dosing for 3 days, clinical cure rates are approximately 80-90% at 1-2 weeks post-treatment. The drug provides sustained local antifungal activity at the vaginal mucosa for the duration of treatment. |
Intravaginal cream: 1 applicatorful (5 g of 2% butoconazole nitrate) intravaginally at bedtime for 3 consecutive days.
| Dosage form | CREAM |
| Renal impairment | No dose adjustment required for renal impairment; pharmacokinetics not significantly altered by decreased GFR. |
| Liver impairment | No specific dose adjustment guidelines available for hepatic impairment; use caution in severe hepatic disease. |
| Pediatric use | Pediatric (≥12 years): same as adult dosing (intravaginal cream 2% once daily for 3 days). Safety and efficacy not established for children <12 years. |
| Geriatric use | No specific dose adjustment required; use same as adult dosing. Consider age-related genital mucosal atrophy and potential for increased systemic absorption in elderly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for FEMSTAT 3 (FEMSTAT 3).
| Breastfeeding | It is not known if butoconazole is excreted in human milk following intravaginal administration. Due to minimal systemic absorption, very low levels in breast milk are expected. The M/P ratio has not been determined. Use with caution in nursing mothers; the developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for the drug. |
| Teratogenic Risk | Butoconazole nitrate is an azole antifungal for intravaginal use. Systemic absorption is minimal (approximately 1.7%), thus fetal exposure is negligible. No teratogenic effects have been observed in animal studies at doses up to 100 mg/kg/day. Pregnancy Category C: Insufficient human data; use only if clearly needed. First trimester: Avoid unless potential benefit outweighs risk. Second and third trimesters: Considered safe for use; no increased risk of major birth defects reported. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to butoconazole or any component of the formulation."]
| Precautions | ["For intravaginal use only; not for ophthalmic or oral use.","Discontinue if hypersensitivity or irritation occurs.","Avoid use during menstruation.","May weaken latex condoms or diaphragms; use alternative contraception for 72 hours after treatment."] |
Loading safety data…
| Fetal Monitoring | No specific fetal monitoring required. Monitor for local irritation or hypersensitivity reactions. If clinical signs of systemic infection occur (fever, chills), evaluate for alternative diagnosis. In pregnancy, monitor for persistence of symptoms; repeat cultures if symptoms do not resolve. |
| Fertility Effects | No known adverse effects on fertility. Animal studies have not shown impaired fertility at therapeutic doses. Butoconazole is used locally for vulvovaginal candidiasis and does not affect ovulation or conception when used as directed. |